Optimization and Validation of Electric Acoustic Stimulation (EAS) Mapping as a Function of Residual Hearing After CI-Implantation

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorLuzerner Kantonsspital

About this trial

The aim of this clinical study is to investigate how the fitting of an EAS (electrical acoustic stimulation) based on electrocochleography (ECochG) thresholds compares to fitting based on pure tone audiogram thresholds in terms of speech intelligibility in quiet and noise. The personal feedback from the study participants regarding the question of better fitting and the resulting sound quality should also be included in the analysis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged between 18-85 years.

Cochlear Implant (CI) candidates with measurable post-operative low-frequency residual hearing (125Hz <65dB, 250Hz <65dB, 500Hz <65dB).

Only patients with MED-EL EAS.

Written informed consent must be obtained prior to study start.

Disqualifiers

Patients with cognitive impairments who, as a result, lack the capacity to make decisions.

Uncooperative patients regarding pure tone audiometry thresholds measurements.

Morbus Menière or intracochlear/ vestibular schwannoma

Trial design

Design model

Crossover

Treatments tested in this trial

  • The objective fitting method of the EAS based on the thresholds of electrocochleography is the intervention of our study.

    Other intervention

    Measured ECochG thresholds will be used in the initial EAS fitting in period 1 for sequence B. For sequence A, the ECochG-based EAS fitting (with up-to-date ECochG thresholds) will take place three months later at the beginning of period 2.

  • The subjective adjustment of an EAS based on thresholds from the pure tone audiogram.

    Other intervention

    The control intervention is the subjective EAS fitting based on PTAs. This is provided to sequence A at the beginning of period 1 baseline and to sequence B at the beginning of period 2.

Treatment groups

12 Participants
are divided into 2 treatment groups
Group A: Sequence A, subjective followed by objective fittingOther 2 interventions
Group B: Sequence B, objective followed by subjective fittingOther 2 interventions

Trial outcomes

Primary outcomes

1

Speech Recognition Threshold (SRT50)

The primary outcome measure is the Speech Recognition Threshold (SRT50) at three months after EAS fitting (either objective or subjective EAS fitting in a cross-over design). The SRT50 measures speech understanding in noise and is defined as the Signal-to-Noise Ratio (measured in dB SNR) which yields 50% speech understanding, as determined by the OLSA test.

Time frame
Three months after EAS fitting

Secondary outcomes

1

Subjective level of auditory benefit

A secondary outcome measure is subjective level of auditory benefit at three months after EAS fitting (either objective or subjective EAS fitting in a cross-over design), as determined using the HISQUI-19 (Hearing Implant Sound Quality Index) questionnaire.

Time frame
Three months after EAS fitting
2

Subjectively preferred EAS fitting method

The subjectively preferred EAS fitting method at the end of the study will be examined.

Time frame
at the end of the study, six months after baseline
3

Post-operative ECochG and PTA tresholds

Post-operative ECochG and PTA thresholds at three months after EAS fitting (either objective or subjective EAS fitting in a cross-over design).

Time frame
Three months after EAS fitting (either objective or subjective EAS fitting)

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Luzerner Kantonsspital

Lead sponsor

MED-EL Elektromedizinische Geräte GesmbH

Collaborator

This trial is not recruiting at the moment. You can still explore other options: